

USE OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR PREVENTION OF PNEUMOCOCCAL DISEASES IN ADULTS IN CURRENT HEALTHCARE PRACTICE

Ya. O. Dziublyk

Abstract

Pneumococcal diseases (PD) are the challenging medical and social problem due to its high incidence and mortality, resulting in severe economic burden. One of the most prevalent forms of PD is community-acquired pneumonia. Major tool in preventing PD is a pneumococcal vaccination. Considering the mechanisms of immune response, one of two types of vaccines, namely conjugated one, is used widely nowadays. The data from clinical trials and practical experience confirmed the high efficacy and good safety of 13-valent conjugated pneumococcal vaccine. Among advantages of this vaccine there are the presence of main pneumococcal serotypes antigens, induction of immune memory, possible concomitant administration with other vaccines, good tolerability and convenience of use.

Key words: pneumococcal diseases, 13-valent conjugated pneumococcal vaccine, efficacy

Ukr. Pulmonol. J. 2014; 1: 49 –54.

Yaroslav A. Dziublyk

National institute of phthisiology

and pulmonology named after F. G. Yanovskyi NAMS of Ukraine

Senior research assistant, PhD

10, M. Amosova str., Kyiv, 03680, Ukraine

Tel/fax: 38 044 275-20-04 , dzublik@yahoo.com